BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

A/ CONCLUD

Met	Ala	Gly	Glu	Leu	Thr	Pro	Glu	Glu	Glu	10
Ala	Gln	Tyr	Lys	Lys	Ala	Phe	Ser	Ala	Val	20
Asp	Thr	Asp	Gly	Asn	Gly	Thr	Ile	Asn	Ala	30
Gln	Glu	Leu	Gly	Ala	Ala	Leu	Lys	Ala	Thr	40
Gly	Lys	Asn	Leu	Ser	Glu	Ala	Gln	Leu	Arg	50
Lys	Leu	Ile	Ser	Glu	Val	Asp	Ser	Asp	Gly	60
Asp	Gly	Glu	Ile	Ser	Phe	Gln	Glu	Phe	Leu	70
Thr	Ala	Ala	Arg	Lys	Ala	Arg	Ala	Gly	Leu	80
Glu	Asp	Leu	Gln	Val	Ala	Phe	Arg	Ala	Phe	90
Asp	Gln	Asp	Gly	Asp	Gly	His	Ile	Thr	Val	100
Asp	Glu	Leu	Arg	Arg	Ala	Met	Ala	Gly	Leu	110
Gly	Gln	Pro	Leu	Pro	Gln	Glu	Glu	Leu	Asp	120
Ala	Met	Ile	Arg	Glu	Ala	Asp	Val	Asp	Gln	130
Asp	Gly	Arg	Val	Asn	Tyr	Glu	Glu	Phe	Ala	140
Arg	Met	Leu	Ala	Gln	Glu					146

3. (Amended) Polypeptide according to claim 1, wherein it is purified from the skin of mammals.

4. (Amended) Polypeptide according to claim 1, wherein it is purified from human skin.

A2

5. (Amended) Polypeptide according to claim 1, wherein it is purified from the human epidermis.

6. (Amended) Natural or synthetic polypeptide whose sequence in part comprises the sequence of polypeptide as described in claim 1.

7. (Amended) Polypeptide according to claim 1, wherein it has a theoretical isoelectric point between 1 and 6.

8. (Amended) Polypeptide according to claim 1, wherein it has a theoretical molecular weight of between 13 and 17 kilodaltons (kD).

10/2/03

9. (Amended) Mixture of polypeptides obtained from the proteolysis of polypeptide as described in claim 1.

10. (Amended) Polypeptide according to claim 1, wherein in its primary sequence, it has at least on calcium-fixing site.

11. (Amended) Polypeptide according to claim 1, wherein it fixes calcium.

12. (Amended) Composition comprising in a physiologically acceptable medium an effective amount of at least one polypeptide as defined in claim 1.

13. (Amended) Composition intended to regulate the impairments of epidermal, normal or pathological proliferation or differentiation, comprising, in a cosmetically acceptable medium, an effective amount of at least one polypeptide as defined in claim 1.

14. (Amended) Composition for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, or neoplasias, comprising in a physiologically acceptable medium, an effective amount of at least one polypeptide as defined in claim 1.

15. (Amended) Composition according to claim 12, which is intended for cosmetic or pharmaceutical application.

16. (Amended) A method for the treatment of dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, or neoplasias, comprising administering an effective amount of at least one polypeptide according to claim 1 to a patient in need of such treatment.

17. (Amended) A method for regulating transglutaminases comprising administering an effective amount of at least one polypeptide according to claim 1 to a patient in need of such regulation.

18. (Amended) The method according to claim 17, wherein the polypeptide or the composition is intended to regulate transglutaminase 3.

19. (Amended) The composition according to claim 12, wherein the polypeptide or the composition is intended to regulate the formation of the corneal layer of the epidermis.

20. (Amended) A method for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, neoplasias, wherein a cosmetic composition as described in claim 12 is applied on the skin of the subject to be treated.

21. (Amended) Isolated deoxyribonucleic acid fragment that codes for the polypeptide as defined in claim 1.

24. (Amended) Cosmetic or pharmaceutical composition, wherein it comprises, in a physiologically acceptable medium, at least one nucleotide sequence as described in claim 22.

25. (Amended) A polypeptide or a mixture of polypeptides comprising at least one deoxyribonucleic acid sequence as described in claim 22.

29. (Amended) A method for preparing a ribonucleic acid comprising using at least one deoxyribonucleic acid sequence as described in claim 22.

30. (Amended) A method for preparing or purifying any molecule that can be bound specifically to at least one isolated purified polypeptide as described in claim 1 or to purified proteolysis fragments of said polypeptide or to a synthetic peptide of said polypeptide.

conclud

31. (Amended) A method for preparing or purifying antiserums or specific monoclonal antibodies comprising using at least one isolated polypeptide or at least one of its proteolysis fragments or any synthetic peptide as described in claim 1.

32. (Amended) Polyclonal or monoclonal antibodies, wherein said antibody recognizes specifically the polypeptide as described in claim 1.